Skip to content

Head to head

BPC-157 against GHK-Cu

Two peptides sold for repair that act on completely different things, a gut-derived pentadecapeptide with an animal literature on tendon and gut, and a copper-binding tripeptide with human topical skin data. The evidence is not interchangeable and neither is the route.

Column A

BPC-157

Body Protection Compound 157

A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting.

Column B

GHK-Cu

Copper Tripeptide-1 (GHK-Cu)

A naturally occurring copper-binding tripeptide widely used in skincare and studied for wound healing and skin remodeling.

Side by side, on the facts we can check

AttributeBPC-157GHK-Cu
CategoryHealing & RecoveryHealing & Recovery
FDA statusNot FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA actionNot an approved drug; permitted as a cosmetic ingredient
Half-lifeUnder 30 minutes in plasma in a two-person pilot; the animal literature describes effects lasting hours to days.Short (topical use)
Molecular weight1,419.5 Da340.38 Da (free peptide); 402.92 Da (the copper complex, PubChem CID 71587328)
MechanismIn animal work BPC-157 promotes angiogenesis, interacts with the nitric oxide system, and raises growth hormone receptor expression and growth factor signaling in tendon fibroblasts. No receptor or molecular target has been identified, which FDA's 2026 evaluation gave as one reason it could not judge biological plausibility. Human mechanistic work is limited to the observation that the peptide was not detectable in plasma after rectal dosing, and to a two-person pilot consistent with a plasma half-life under 30 minutes, against effects that animal studies describe as lasting hours to days.Delivers copper and modulates genes involved in tissue remodeling, stimulating collagen and glycosaminoglycan synthesis and supporting wound repair.
Human studies cited50
Legal status, USNot approved; research use onlyPermitted in cosmetics; not an approved drug
open the BPC-157 profileopen the GHK-Cu profile

Frequently asked questions

What is the difference between BPC-157 and GHK-Cu?

BPC-157: A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting. GHK-Cu: A naturally occurring copper-binding tripeptide widely used in skincare and studied for wound healing and skin remodeling.

Which has stronger research evidence, BPC-157 or GHK-Cu?

This database does not grade compounds. It counts what was run in people: 5 of the 12 studies cited on the BPC-157 profile were human work, against 0 of 3 for GHK-Cu. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.

Are BPC-157 and GHK-Cu FDA-approved?

BPC-157: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action. GHK-Cu: Not an approved drug; permitted as a cosmetic ingredient.

Related posts

Blog articles that cover BPC-157 or GHK-Cu, newest first.

Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.